All participants | Conventional treatment | Intensive treatment | ||||
---|---|---|---|---|---|---|
HR (95% C.I.) | p | HR (95% C.I.) | p | HR (95% C.I.) | p | |
MACE | ||||||
ASV | 1.34 (1.06–1.66) | 0.01 | 1.50 (1.07–2.05) | 0.02 | 1.15 (0.79–1.62) | 0.45 |
SD_bw | 1.55 (1.20–1.96) | 0.0009 | 1.79 (1.22–2.55) | 0.004 | 1.40 (0.97–1.98) | 0.08 |
CVAR | 1.50 (1.18–1.88) | 0.001 | 1.65 (1.18–2.26) | 0.005 | 1.40 (0.94–2.03) | 0.09 |
REL_ASV | 1.32 (1.03–1.66) | 0.03 | 1.45 (1.03–1.97) | 0.03 | 1.11 (0.72–1.63) | 0.63 |
VIM | 1.50 (1.17–1.88) | 0.002 | 1.64 (1.17–2.23) | 0.005 | 1.40 (0.94–2.04) | 0.10 |
All-cause death | ||||||
ASV | 1.25 (1.03–1.50) | 0.03 | 1.50 (1.17–1.89) | 0.002 | 1.05 (0.73–1.46) | 0.78 |
SD_bw | 1.42 (1.14–1.76) | 0.003 | 1.69 (1.27–2.18) | 0.0005 | 1.18 (0.82–1.66) | 0.37 |
CVAR | 1.39 (1.11–1.70) | 0.004 | 1.59 (1.22–2.02) | 0.0009 | 1.13 (0.78–1.60) | 0.50 |
REL_ASV | 1.32 (1.08–1.60) | 0.008 | 1.59 (1.23– 2.01) | 0.0006 | 1.10 (0.76–1.54) | 0.60 |
VIM | 1.38 (1.11–1.69) | 0.005 | 1.59 (1.22–2.01) | 0.001 | 1.13 (0.78–1.59) | 0.51 |